Entering text into the input field will update the search result below

Myriad Genetics hit by CMS concerns, patent suit

Dec. 02, 2013 10:42 AM ETMyriad Genetics, Inc. (MYGN) StockMYGNBy: Colin Lokey, SA News Editor2 Comments
  • Shares of Myriad Genetics (MYGN -4.2%) are struggling in morning trading.
  • Not surprisingly, questions about BRCA reimbursement and patents look to be behind the move lower.
  • According the market chatter, Piper thinks the "'final' National Fee Schedule price of $1,438 for BRACAnalysis is likely an error."
  • For those interested, this looks to be coming from code 81211 on the 2014 Clinical Diagnostic Laboratory Fee Schedule, available here (it's in the Excel sheet).
  • Also, Invitae Corporation has filed an action in district court seeking "a declaration that certain MYGN patents relating to the BRCA1/2 and MUTYH genes are invalid." (PR)

Recommended For You

About MYGN Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
MYGN--
Myriad Genetics, Inc.